Caspase-1 Interdomain Linker Cleavage is Required for Pyroptosis
Overview
Biology
Cell Biology
Molecular Biology
Authors
Affiliations
Pathogen-related signals induce a number of cytosolic pattern-recognition receptors (PRRs) to form canonical inflammasomes, which activate pro-caspase-1 and trigger pyroptotic cell death. All well-studied inflammasome-forming PRRs oligomerize with the adapter protein ASC (apoptosis-associated speck-like protein containing a CARD) to generate a large structure in the cytosol, which induces the dimerization, autoproteolysis, and activation of the pro-caspase-1 zymogen. However, several PRRs can also directly interact with pro-caspase-1 without ASC, forming smaller "ASC-independent" inflammasomes. It is currently thought that little, if any, pro-caspase-1 autoproteolysis occurs during, and is not required for, ASC-independent inflammasome signaling. Here, we show that the related human PRRs NLRP1 and CARD8 exclusively form ASC-dependent and ASC-independent inflammasomes, respectively, identifying CARD8 as the first canonical inflammasome-forming PRR that does not form an ASC-containing signaling platform. Despite their different structures, we discovered that both the NLRP1 and CARD8 inflammasomes require pro-caspase-1 autoproteolysis between the small and large catalytic subunits to induce pyroptosis. Thus, pro-caspase-1 self-cleavage is a required regulatory step for pyroptosis induced by human canonical inflammasomes.
The Selective 3-MST Inhibitor I3MT-3 Works as a Potent Caspase-1 Inhibitor.
Otani K, Komatsu R, Noguchi T, Suzuki W, Hirata Y, Matsuzawa A Int J Mol Sci. 2025; 26(5).
PMID: 40076859 PMC: 11899812. DOI: 10.3390/ijms26052237.
Pandey A, Li Z, Gautam M, Ghosh A, Man S Immunol Rev. 2024; 329(1):e13406.
PMID: 39351983 PMC: 11742652. DOI: 10.1111/imr.13406.
Inflammasome activity regulation by PUFA metabolites.
Atalay Ekiner S, Gegotek A, Skrzydlewska E Front Immunol. 2024; 15:1452749.
PMID: 39290706 PMC: 11405227. DOI: 10.3389/fimmu.2024.1452749.
Inflammasome components as new therapeutic targets in inflammatory disease.
Coll R, Schroder K Nat Rev Immunol. 2024; 25(1):22-41.
PMID: 39251813 DOI: 10.1038/s41577-024-01075-9.
Multiple sclerosis: the NLRP3 inflammasome, gasdermin D, and therapeutics.
Brint A, Greene S, Fennig-Victor A, Wang S Ann Transl Med. 2024; 12(4):62.
PMID: 39118955 PMC: 11304424. DOI: 10.21037/atm-23-1960.